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Abstract
CRISPR-Cas systems have become widely used across all fields of biology as a genome
engineering tool. With its recent demonstration in the Gram positive industrial workhorse
Bacillus subtilis, this tool has become an attractive option for rapid, markerless strain engi-
neering of industrial production hosts. Previously described strategies for CRISPR-Cas9
genome editing in B. subtilis have involved chromosomal integrations of Cas9 and single
guide RNA expression cassettes, or construction of large plasmids for simultaneous trans-
formation of both single guide RNA and donor DNA. Here we use a flexible, co-transforma-
tion approach where the single guide RNA is inserted in a plasmid for Cas9 co-expression,
and the donor DNA is supplied as a linear PCR product observing an editing efficiency of
76%. This allowed multiple, rapid rounds of in situ editing of the subtilisin E gene to incorpo-
rate a salt bridge triad present in the Bacillus clausii thermotolerant homolog, M-protease. A
novel subtilisin E variant was obtained with increased thermotolerance and activity.
Introduction
The clustered regularly interspaced short palindromic repeats (CRISPR)-associated (Cas) sys-
tems of adaptive immunity in bacteria have become widely used across all fields of biology as a
genome editing tool since demonstration of its use as a RNA-guided DNA endonuclease in
2012 [1]. The technique, based on the type II CRISPR-Cas9 system from Streptococcus pyo-
genes, makes use of the host DNA double-strand break (DSB) repair machinery to introduce
mutations within the DNA sequence. DSBs can be repaired by the error-prone non-homolo-
gous end joining (NHEJ) or homology directed DNA repair (HDR) mechanisms of the cell.
NHEJ can introduce random mutations during repair, while HDR allows the introduction of
selected modifications in the presence of an engineered template with chromosome homology
regions flanking the desired mutations. Uptake of CRISPR-Cas9 genome editing in the Gram
positive model organism Bacillus subtilis was however relatively slow, perhaps, in part, due to
the high number of well-established genomic modification tools already available. However,
recently several publications were released in quick succession showing the development of
the CRISPR-Cas9 system in this host [2–6]. These initially showed use of the catalytically active
Cas9 for large scale genomic deletions, small and large DNA insertions, gene silencing by
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introduction of a stop codon and engineering of increased resistance to bacteriophage SPP1
[2–6]. Additionally, the catalytically inactivated ‘dead’ Cas9 (dCas9) was used to allow pheno-
typic analysis of all essential genes in B. subtilis. This was performed by dCas9 binding at the
target region within the gene and not inducing a DSB, subsequently reducing the level of tran-
scription from that gene and any other genes downstream in the same operon. [7].
Two methodologies have been exemplified in B. subtilis using the catalytically active Cas9.
First, Westbrook et al. (2016) demonstrated a system where a single plasmid simultaneously deliv-
ers an integration cassette for expression of the chromosome targeting crRNA and the donor
DNA (dDNA) for DSB repair, in a strain where the cas9 gene and tracrRNA, which associates
Cas9 to the crRNA, was previously integrated in the chromosome [3]. Others have used an alter-
native system where cas9 and sgRNA (single guide RNA where tracrRNA and crRNA are com-
bined as a single fragment) expression cassettes, as well as dDNA, are delivered in a single
temperature sensitive plasmid [2,5,6]. With the first method, the crRNA expression cassette must
be removed with a subsequent transformation step to restore the integration site before next
rounds of editing are possible. The second strategy, although more amenable to multiple rounds
of editing, involves a 2-step construction of a large shuttle vector to introduce the sgRNA and
dDNA [2]. Here, we present a simple and straightforward method which allows rapid in situ edits
of the genome, using a plasmid which can target any loci within B. subtilis in a single cloning step,
and without previous genome modifications. During the editing process, this plasmid transcribes
the sgRNA under the control of the strong constitutive promoter, Pveg, and utilises the basal
expression level of the Pgrac promoter to regulate cas9 expression. The dDNA in the form of a lin-
ear PCR product is co-transformed with the plasmid, providing the template for DSB repair.
The use of CRISPR-Cas9 mediated genome editing using this approach was first exempli-
fied by knock-out of the α-amylase encoding gene, amyE. Subsequently our system was shown
to be compatible for engineering of industrial production hosts by in situ modification of the
aprE gene. This encodes for the industrially relevant enzyme subtilisin E, used globally within
the detergent industry. As the wild type enzyme can be broken down by detergent formula-
tions and heat, subtilisin variants with improved thermostability and pH tolerance have long
been of interest. Subtilisin E has been widely used as a target for protein engineering experi-
ments [8]. A salt-bridge triad (Arg19-Glu271-Arg275), identified in the subtilisin E homolog
from Bacillus clausii (M-protease), was found to be a contributor for the characteristic thermo-
tolerance of this enzyme [9]. Here, we use CRISPR-Cas9 mediated genome editing to replace
the respective residues in subtilisin E (Gln125-Gln377-Gln381), and evaluate the effect of the
salt bridge on the thermostability and activity of the new variant. This work illustrates the use
of a simple CRISPR-Cas9 system for B. subtilis rapid, in situ protein engineering, which is at
the core of industrial biotechnology to provide new, suitable and competitive biocatalysts.
Materials and methods
Strains and media
The strains and plasmids used in this study are listed in Table 1. All oligonucleotides used in this
study are listed in S1 Table. Escherichia coli Top10 strains were used to construct recombinant
plasmids. Bacterial cells were cultured in Lysogeny broth (LB) or LB agar (VWR) media at 37˚C.
Unless otherwise stated, the following antibiotics were added to the media when required: ampi-
cillin (200 μg/mL), chloramphenicol (10 μg/mL), or spectinomycin (100 μg/mL).
Plasmid construction
Unless otherwise stated, plasmid construction was performed as described in Sambrook and
Russell [12]. DNA oligonucleotides were purchased from Sigma-Aldrich. The reagents for
CRISPR-Cas9 enabled protein engineering in Bacillus subtilis
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PCR, restriction digest, Gibson assembly, DNA phosphorylation and ligation were purchased
from New England Biolabs (NEB). DNA purification was performed using the kits from NEB.
DNA sequences were confirmed by Source Bioscience.
pBAC0001 was constructed by Gibson assembly to remove the SapI sites present in pHT01
(MoBiTec) [13]. PCR products for Gibson assembly were prepared from pHT01 using oligo-
nucleotides oMAP0002/0003/0004/0005.
pBAC0008 plasmid was constructed using the inABLE plasmid assembly method [14].
Individual 5’ truncated parts were prepared by PCR followed by restriction digest at 5’ and 3’
regions with SapI. These parts were ligated to phosphorylated and annealed oligonucleotides
at each terminus, containing 3 nt and 16 nt single strands at the 5’ and 3’ ends, respectively.
The part- oligonucleotides fusions were annealed at the homologous 16 nt overhangs for 1
hour at 37˚C, and used to transform electrocompetent E. coli.
Table 1. Strains and plasmids used in this study.
Strain/ Plasmid Genotype Reference
Strains
B. subtilis
168 trpC2 Laboratory stock
BAC0094 B. subtilis 168 with aprE Q125R variant. This work
BAC0095 B. subtilis 168 with aprE Q377E and Q381R variant. This work
BAC0097 BAC0095 with aprE Q125R, Q377E and Q381R variant This work
BAC0114 B. subtilis 168 ΔaprE::aad9 This work
BAC0119 BAC0114, pBAC0059. This work
BAC0120 BAC0114, pBAC0060. This work
BAC0121 BAC0114, pBAC0068. This work
BAC0122 BAC0114, pBAC0069. This work
E. coli
Top10 F- mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacX74 recA1 araD139 Δ(araleu) 7697 galU galK rpsL (StrR) endA1 nupG Invitrogen
Plasmids
pHT01 E. coli/B. subtilis shuttle vector carrying Pgrac and lacI, bla, cat. MoBiTec
pdCas9-bacteria tetR; dCas9 (S. pyogenes); rrnB T1; p15a ori; cat [10]
pING0001 Pbad; rrnB T1; rrnB T2; bla; pBR327 ori; araC Ingenza Ltd.
pING0002 Pbad; aphAI; pMB1 ori; araC Ingenza Ltd.
pDR111 bla; 5’ amyE; aad9; Pspac;lacI; 3’ amyE [11]
pBAC0001 pHT01 with SapI sites removed. This work
pBAC0008 pBAC0001 with rrnB T1 T2; sgRNA Cas9 handle; protospacer cloning site; Pveg This work
pBAC0013 pdCas9-bacteria with catalytically active cas9. This work
pBAC0015 pBAC0008 with cas9 (S. pyogenes) from pBAC0013. Cas9 expression regulated by the Pgrac promoter. This work
pBAC0027 pBAC0015 with amyE-1 sgRNA DNA. This work
pBAC0035 pBAC0015 with non-targeting sgRNA DNA. This work
pBAC0041 pBAC0015 with amyE-2 sgRNA DNA. This work
pBAC0047 pBAC0015 with amyE-3 sgRNA DNA. This work
pBAC0054 pBAC0015 with aprE-1 sgRNA DNA. This work
pBAC0055 pBAC0015 with aprE-2 sgRNA DNA. This work
pBAC0059 pHT01 with aprE (native) from B. subtilis 168 with ATG start codon. This work
pBAC0060 pHT01 with aprE (Q125R, Q377E and Q381R variant) from BAC0097 with ATG start codon. This work
pBAC0068 pHT01 with aprE (Q125R variant) from BAC0094 with ATG start codon. This work
pBAC0069 pHT01 with aprE (Q377E and Q381R variant) from BAC0095 with ATG start codon. This work
https://doi.org/10.1371/journal.pone.0210121.t001
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pBAC0008 consisted of four parts: 1. the E. coli/B. subtilis shuttle vector backbone from
pBAC0001; 2. the LacI repressor and isopropyl β-D-1-thiogalactopyranoside (IPTG) inducible
Pgrac promoter from pBAC0001, including a multiple cloning site; 3. the bidirectional strong
rrnB T1 and T2 terminators; 4. the sgRNA expression module consisting of a kanamycin resis-
tance gene flanked by AarI sites expressed under the control of the Pveg promoter, and the
’Cas9 handle’ section of the sgRNA (5’ truncated parts were prepared by PCR from the indi-
cated template and oligonucleotides: 1. pBAC0001 with oMAP0010/0011; 2. pBAC0001 with
oMAP0018/0019; 3. pING0001 with oMAP0024/0025; 4. pING0002 with oMAP0030/0031.
Parts were ligated at 5’ and 3’ respectively with annealed oligonucleotides: 1. oMAP0008/0009
and oMAP0014/0015; 2. oMAP0016/0017 and oMAP0020/0021; 3. oMAP0022/0023 and
oMAP0048/0049; 4. oMAP0050/0051 and oMAP0052/0053.)
pBAC0013 was constructed by converting the catalytically inactive dcas9 gene from
pdCas9-bacteria to active cas9. This was done by introducing mutations A10D, A840H and
removing a BamHI site by PCR (oligonucleotides oMAP0062/0063/0064/0065/0066/0067) and
a subsequent 3-part Gibson Assembly (pdCas9-bacteria was a gift from Stanley Qi (Addgene
plasmid # 44249) [10].
Subsequently the catalytically active cas9 gene was amplified with oligonucleotides
oMAP0073/0074, introducing a BsaI site and XbaI recognition sites at the 5’ and 3’ end of the
gene, respectively. The amplified cas9 was digested with BsaI and XbaI, pBAC0008 was
digested with BamHI and XbaI and both fragments were ligated with T4 DNA ligase, yielding
pBAC0015.
To construct the subtilisin E overexpression plasmids pBAC0059, pBAC0060, pBAC0068
and pBAC0069, each subtilisin E variant and the wild type (WT) gene was amplified from
chromosomal DNA derived from the relevant strain (Table 1) with oligonucleotides
oMAP0186/0203, oMAP0200/0203, oMAP0186/0203, and oMAP0200/0203 respectively, each
set containing 5’-BamHI and 3’-XmaI recognition sites. Oligonucleotides oMAP0203 also
replaced the native GTG start codon with an ATG codon. The genes were cloned into pHT01
using the BamHI and XmaI recognition sites in the multiple cloning site of the plasmid.
CRISPR-Cas9-Mediated gene editing in B. subtilis
Analysis of editing efficiency. For CRISPR-Cas9 mediated editing efficiency analysis,
plasmids targeting the α-amylase amyE in B. subtilis were constructed. Plasmid pBAC0015
was digested with AarI (Thermo Fisher Scientific) to remove the kanamycin resistance gene
and ligated to two annealed and phosphorylated DNA oligonucleotides of 24 nucleotides. The
annealed oligonucleotides consisted of the 20 nucleotide protospacer region for targeting of
the Cas9 protein and 4 nucleotides to generate a single stranded overhang for compatibility
with the AarI digested vector. DNA phosphorylation was performed using T4 Polynucleotide
Kinase according to the manufacturer’s instructions. The protospacer regions were identified
using the online tool CRISPR-ERA: a comprehensive designer tool for CRISPR genome edit-
ing, (gene) repression, and activation, and selected based on the proximity to the desired mod-
ification [15]. The oligonucleotide pairs oMAP0089/0091, oMAP0125/0127 and oMAP0140/
0142 yielded plasmids pBAC0027, pBAC0041 and pBAC0047 respectively. As a positive con-
trol for transformation efficiency, a sgRNA designed not to target the B. subtilis 168 chromo-
some was inserted into pBAC0015 with the oligonucleotide pair oMAP0145/0147, yielding
pBAC0035. dDNA to introduce stop codons and repair the sgRNA-targeted Cas9 DSB were
constructed by overlap extension PCR (OE-PCR) of two DNA fragments as described by Bryk-
sin and Matsumura [16]. The desired edits were introduced in the homology overlap of the
two DNA fragments. These included the silent mutation of the 5’-NGG-3’ protospacer
CRISPR-Cas9 enabled protein engineering in Bacillus subtilis
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adjacent motif (PAM) site to prevent continuous cutting by the RNA-guided Cas9 endonucle-
ase. OE-PCR products from oligonucleotides sets oMAP0121/0122/0123/0124, oMAP0121/
0122/0128/0129 and oMAP0121/0122/0143/0144 were used alongside pBAC0027, pBAC0041
and pBAC0047 respectively. Genome editing was carried out in triplicate by co-transforming
naturally competent B. subtilis 168 with 200 ng CRISPR-Cas9/sgRNA plasmid DNA and 1 μg
dDNA [17]. Transformants were spread on LB agar plates supplemented with 1% soluble
potato starch (VWR) and chloramphenicol (5 μg/mL). IPTG was not added for cas9 expression
induction to limit cellular burden and it was found that basal expression under the Pgrac pro-
moter was sufficient for cas9 expression. Effective knock-out of amyE by stop codon introduc-
tion was determined by staining transformation plates with iodine [18].
Editing of aprE. Using the approach described above, CRISPR-Cas9 mediated editing of the
aprE gene in B. subtilis 168 was carried out. The oligonucleotide pairs oMAP0150/0151 and
oMAP0156/0157 were ligated with pBAC0015 prepared as above, yielding plasmids pBAC0054
and pBAC0055 respectively. dDNA OE-PCR products from oligonucleotides sets oMAP0152/
0153/0154/0155 and oMAP0158/0159/0160/0161 were used alongside pBAC0054 and pBAC0055
respectively. Editing was confirmed by PCR of the aprE gene with oligonucleotides oMAP0152/
0161, followed by sequencing using oligonucleotides oMAP0158 and oMAP0155 for candidates
edited with pMAP0054 and pMAP0055 respectively. The CRISPR-Cas9/sgRNA plasmid was
removed from the edited strain by promoting plasmid loss in LB supplemented with 1 mM IPTG
overnight. Here the presence of IPTG encourages curing by introducing the pressure of protein
expression without the presence of chloramphenicol to retain the plasmid within the cell. Plasmid
loss was confirmed by counter plating on LB agar plates with and without chloramphenicol before
a subsequent round of editing. Following the second round of editing, these mutations and those
introduced previously were confirmed to be present by sequencing (as above).
Protein purification
The three subtilisin E variants and WT protein were overexpressed in the aprE knock-out
strain BAC0114. BAC0114 was constructed by transformation of B. subtilis 168 with OE-PCR
product containing a spectinomycin resistance cassette flanked by homology arms upstream
and downstream of aprE (oligonucleotides oMAP0217/0218/0219/0220/0221/0222). Confir-
mation of aprE deletion was obtained by purification of the genomic DNA for BAC0114 and
PCR of ΔaprE::aad9 locus with oligonucleotides oMAP0670 (hybridising to aad9) and
oMAP0671 (hybridising to the genome, upstream of the homology arm region). Additionally,
PCR with oligonucleotide pair oMAP0217/0220 (hybridising to the extremities of the homol-
ogy arm region) revealed the expected increase in product size for ΔaprE::aad9 relative to the
WT PCR product. This strain was then transformed with plasmids pBAC0059/0060/0068/
0069, resulting in strains BAC0119/0120/0121/0122 respectively. These strains were grown for
24 hours at 37˚C with agitation (250 rpm) in 20 mL LB supplemented with chloramphenicol.
The supernatant was clarified and dialysed overnight into 100 mM Tris-HCl with 150 mM
sodium chloride at pH 8. The dialysed supernatant was concentrated to 5 mL with Amicon
Ultra-15 (10 kDa membrane (Merck)), filtered through a 0.2 μm filter (Sartorius). This was
loaded onto a HiPrep Sephacryl S-200 HR, 120 mL 16/60 size exclusion column (GE Health-
care), eluted in the same buffer composition used for dialysis and fractions found to contain
subtilisin E were pooled. Protein concentration was determined by absorbance at 280 nm.
Thermal shift assay
The fluorescence-based thermal shift assay was used to determine the melting temperature
(Tm) of the subtilisin E variants and WT [19]. The assay reaction was prepared in a total
CRISPR-Cas9 enabled protein engineering in Bacillus subtilis
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volume of 20 μL (18 μL purified subtilisin E variant in purification buffer, 1 μL 100 mM cal-
cium acetate and 1 μL 1:50 SYPRO Orange (Sigma-Aldrich)). The assay was performed with
six technical replicates for each variant. The reaction was analysed using the Pikoreal 96
(Thermo Scientific) which recorded changes in fluorescence with increasing temperature
(40˚C—80˚C in increments of 0.2˚C, held for 6 seconds at each point).
Subtilisin E activity assay
Subtilisin E variants and WT activity was determined by casein degradation as described by
Cupp-Enyard [20].
Residual enzyme activity tests
Residual enzyme activity was analysed by incubation of the purified enzymes at 55˚C for 10,
20, 40, and 60 minutes prior to the activity assay.
Results
Analysis of CRISPR-Cas9 mediated gene editing efficiency
To analyse CRISPR-Cas9 mediated gene editing efficiency using our co-transformation sys-
tem, the amyE gene encoding an α-amylase was selected for knock-out using a starch degrada-
tion assay. The three tested amyE targeting plasmids (pBAC0027/0041/0047) yielded on
average an editing efficiency of 63.9%, 89.2% and 74.4% when co-transformed with dDNA
(Fig 1).
Rapid in situ modification of aprE with CRISPR-Cas9
The crystal structures for B. subtilis subtilisin E (PDB ID 1SCJ) and its B. clausii homolog, M-
protease (PDB ID 1WSD), were overlaid using Swiss-Pdb viewer (Fig 2) [21–23]. The residues
corresponding to the salt-bridge triad (R19-E271-R275) that have previously been shown to
contribute towards M-protease thermotolerance were identified in the subtilisin E structure
(Q125-Q377-Q381) [9].
A CRISPR-Cas9 mediated chromosome editing strategy was designed to introduce the
mutations Q125R, Q377E and Q381R. pBAC0015 was altered to include the oligonucleotide
pairs oMAP0150/oMAP0151 or oMAP0156/oMAP0157, yielding plasmids pBAC0054 (target-
ing Q125R locus) and pBAC0055 (targeting Q377E and Q381R locus) respectively. Due to
their proximity, Q377E and Q381R modifications were combined into a single CRISPR-Cas9
mediated editing step with a single dDNA. Q125R was modified in a separate editing step. The
desired edits, included the modification of the PAM site to prevent continuous cutting by the
RNA-guided Cas9 endonuclease, were introduced in the homology overlap of the two DNA
fragments prepared using PCR. These were subsequently combined using OE-PCR and co-
transformed alongside the respective plasmid (Fig 2). OE-PCR products from oligonucleotides
sets oMAP0152/0153/0154/0155 and oMAP0158/0159/0160/0161 were used alongside
pBAC0054 and pBAC0055 respectively. Following an efficient curing process yielding strains
BAC0094 (Q125R) and BAC0095 (Q377E and Q381R) respectively, a second round of editing
using the second set of editing plasmid and dDNA yielded the final strain (BAC0097) contain-
ing all three modified residues. All screened colonies were found to contain the desired muta-
tions following sequencing.
This system represents a rapid technique for in situ protein modifications within B. subtilis
168. Once the Cas9-sgRNA expression plasmid is prepared, the same region on the
CRISPR-Cas9 enabled protein engineering in Bacillus subtilis
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chromosome can be targeted with alternative, rapidly prepared, linear dDNA templates con-
veying novel modifications of interest.
Thermotolerance of subtilisin E variants
The thermotolerance of purified subtilisin E variants and WT (purification described in mate-
rials and methods section) was analysed by the thermal shift assay (Fig 3). Variants Q377E
+Q381R and Q125+Q377E+Q381R showed increased thermotolerance when compared to the
WT and Q125R proteins, confirming the importance of residues E377 and R381 for protein
stability at higher temperatures. In contrast, the Q125R variant showed no increase in thermo-
tolerance, most likely as there is no mutated residue with which it can form salt bridge.
The average Tm for each variant was established by performing a melt curve analysis of the
thermal shift assay data (Fig 3). An increase in Tm of up to 1.4˚C was established and verified
as statistically significant by use of an unpaired t test with Welch’s correction (Fig 4). The
greatest increase in Tm of 1.4˚C was found in the Q377E + Q381R variant (54.8˚C, P value =<
0.0001), while the full salt bridge triad variant showed an increase of 1.2˚C (54.6˚C, P value =
< 0.0001). The Q125R variant showed no significant difference in Tm when compared to the
WT (53.4˚C and 53.5˚C respectively).
Activity retention of subtilisin E variants
To ensure the introduced mutations had not negatively affected catalytic efficiency of the
enzyme, the activity for each variant and the WT was established under neutral conditions
(pH 7.5, 37˚C) by measuring the degradation of casein using Folin’s reagent (Fig 5) [20]. Both
the Q125R and Q125+Q377E+Q381R variants were 60% less active when compared to the
WT, suggesting that the Q125R residue is important for catalytic activity. The Q377E+Q381R
variant showed an increase in protease activity of 46.5% (P value =< 0.0001).
Fig 1. Number of transformants and editing efficiencies obtained following CRISPR-Cas9 genome editing of
amyE. White bars represent the number of CFU obtained following transformation of three amyE targeting plasmids
(pBAC0027/0041/0047) with or without editing template (dDNA) to introduce stop codons and repair the sgRNA-
targeted Cas9 DSB. A plasmid containing a non-targeting sgRNA (pBAC0035) was transformed to monitor
transformation efficiency. The blue bars represent the editing efficiency of the obtained CFU determined by observing
the presence or absence of a halo following iodine staining of the starch-containing transformation plates. Error bars
indicate the standard deviation between three transformations.
https://doi.org/10.1371/journal.pone.0210121.g001
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Residual enzyme activity was measured following incubation of the enzyme variants at
55˚C (Fig 6). Variant Q377E + Q381R was found to be the best at retaining its enzymatic activ-
ity when incubated for over 20 minutes. An improvement of 12.1% and 15.1% in activity rela-
tive to the WT following incubation for 40 and 60 minutes respectively was noted. The Q125
+ Q377E + Q381R variant showed a 34.9% decreased in activity relative to the WT following
20 minutes incubation. Similarly, the Q125R variant showed a decreased in activity of 54.1% at
20 minutes incubation.
Discussion
We have developed a B. subtilis specific, rapid, in situ protein engineering technique based on
the ground breaking CRISPR-Cas9 technology. The rapid engineering of established and
Fig 2. Design and CRISPR-Cas9 editing process of aprE. A) B. subtilis 168 subtilisin E crystal structure (green) and overlay with B. clausii M protease crystal structure
(cyan), with the associated salt bridge (dashed yellow line). B) Design of the sgRNA and dDNA OE-PCR product for CRISPR-Cas9 genome editing. The two rounds of
editing are described in blue and red, the PAM recognition sequences for each sgRNA was also targeted for disruption in each dDNA. C) Description of editing process
where the second round of editing occurs following a blunt DSB by sgRNA guided Cas9.
https://doi.org/10.1371/journal.pone.0210121.g002
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novel industrially relevant proteins yielding markerless, and potentially non-GMO compliant
strains, is an attractive proposition for industrial biotechnology. This is due to the lowering in
Fig 3. Thermal shift assay of the thermostability of each subtilisin E variant and WT. Increase in fluorescence was
detected as hydrophobic regions of the protein were exposed as the protein denatured. The protein melting
temperature of each variant and WT was calculated with a melt curve analysis, determining the peak rate of protein
unfolding per temperature increase. Error bars indicate the standard deviation between six replicates.
https://doi.org/10.1371/journal.pone.0210121.g003
Fig 4. Average Tm between Subtilisin variants and WT replicates. The Tm of each subtilisin E variant and WT was
calculated as the temperature at which the peak rate of protein unfolding was observed for each of six replicated. Error
bars indicate the standard deviation. ���� = p value summary (p =< 0.0001) following unpaired t test with Welch’s
correction.
https://doi.org/10.1371/journal.pone.0210121.g004
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costs and time associated with product development and governmental regulatory compliance,
while increasing the time a product is in production.
Initial exemplification of our system on the α-amylase encoding gene, amyE, showed an
average editing efficiency of 76% across the three targeted PAM sites selected. While our co-
transformation-based approach to genome editing may result in lower transformation efficien-
cies due to the requirement that both plasmid and dDNA molecules enter the cell, the rate of
editing efficiency observed enables a high degree of confidence that most colonies obtained
Fig 5. Protease activity assay. Protease activity at pH 7.5, 37˚C for 10 minutes. Normalised for protein concentration
determined by absorbance at 280 nm. Absorbance units (AU) determined at 660 nm. ���� = p value summary (p =<
0.0001) following unpaired t test with Welch’s correction. Error bars indicate standard deviation between triplicates.
https://doi.org/10.1371/journal.pone.0210121.g005
Fig 6. Residual protease activity assay. Residual protease activity under neutral conditions following incubation at
55˚C for various lengths of time, determined by a casein degradation enzymatic assay. Error bars indicate standard
deviation between technical triplicates.
https://doi.org/10.1371/journal.pone.0210121.g006
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have been edited as designed. This system, where one round of plasmid construction is
required and transformed alongside an easily prepared PCR product, represents an alternative
to the B. subtilis CRISPR-Cas9 genome editing strategies published to date. These involve pre-
vious chromosome integration of the cas9 gene and subsequent eviction of cas9/tracrRNA and
crRNA expression cassettes after editing, or a two-step plasmid construction to introduce the
sgRNA expression cassette and dDNA [2,3,5,6].
In under a week we carried out two rounds of in situ CRISPR-Cas9 editing of the subtilisin
E gene, aprE. A salt bridge triad was introduced and the Q337E + Q381R variant showed an
increase of 46.5% in subtilisin E activity, as well as a 1.4˚C increase in thermostability. To the
best of our knowledge these modifications have not been combined before in B. subtilis subtili-
sin E.
Interestingly, the Q125R + Q377E + Q381R variant did not retain its activity levels to the
same level as the Q377E + Q381R variant. Indeed, in both variants where the Q125R mutation
is introduced a drastic drop in enzyme activity retention was observed (Figs 5 and 6), indicat-
ing a vital catalytic activity role for residue Q125 within B. subtilis subtilisin E. A similar study
of salt bridges in subtilisin E was performed by Erwin et al., where mutations Q125E + Q377E
formed a salt bridge based on X-ray crystal structure, but resulted in a 1.2˚C drop in thermoto-
lerance [24].
In summary, this method for genomic modifications by CRISPR-Cas9 allows rapid, in situ
protein engineering of industrially relevant strains. Furthermore, discovery and optimisation
of new molecular biology tools such as the work presented here, increases the speed and effi-
ciency at which novel biocatalysts can be developed for sustainable bioprocesses.
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